Ionis Posts $243M in Third-Quarter Revenue
IONS is trading near its 52-week low of $38.305 (3.4% below the low).
Summary
Ionis reported third-quarter revenue of $243M, up 55% from a year earlier. The quarter showed a loss of 66 cents per share and operating expenses of USD 373 Million. The company lowered its TRYNGOLZA 2026 sales guidance while reaffirming its 2026 total revenue, operating loss and cash guidance. The quarter lands after a heavy stretch of pipeline news: FDA approval of zilganersen in September, positive Phase 3 data for ulefnersen and sefaxersen, and the pelacarsen Phase 3 failure with Novartis. The stock sits near its 52-week low, so the revenue line and any commentary on TRYNGOLZA and DAWNZERA launch costs will carry weight.
At the time of this announcement, IONS was trading at $37.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $38.31 to $86.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.